SANA vs VRTX
SANA: Sana Biotechnology is developing ex vivo and in vivo engineered cell therapy platforms to transform the treatment of diseases like type 1 diabetes, oncology, and autoimmune conditions. VRTX: Vertex Pharmaceuticals develops transformative medicines for serious genetic diseases, with a dominant pipeline anchored in cystic fibrosis treatments and groundbreaking gene-editing therapies for blood disorders and pain.
Side-by-side fundamentals
| Metric | SANA | VRTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $3.12 | $472.57 | |
| Market cap as of 2026-07-23 | $868M | $121.4B | |
| P/E as of 2026-07-23 | n/a | 27.98 | |
| PEG as of 2026-07-23 | -0.55 | 2.31 | SANA lower |
| Net margin as of 2026-07-23 | n/a | +35.5% | |
| Gross margin as of 2026-07-23 | n/a | +86.2% | |
| Operating margin as of 2026-07-23 | n/a | +38.3% | |
| ROE as of 2026-07-23 | -161.9% | +23.9% | VRTX higher |
| ROA as of 2026-07-23 | -61.0% | +17.2% | VRTX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.01 | SANA lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +10.1% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +10.4% | |
| Beta as of 2026-07-23 | 2.12 | 0.30 | |
| 1-year return as of 2026-07-22 close | -28.8% | +0.5% | VRTX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.